Biogen BIIB Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.38B+12.4% | $3.01B-22.1% | $3.86B+40.0% | $2.76B+6.2% | $2.6B+9.4% | ||
| $900M+11.5% | $807.2M+727% | $97.6M— | —— | —— | ||
| $139.5M-4.1% | $145.4M-10.4% | $162.3M+7.8% | $150.6M+28.3% | $117.4M+25.0% | ||
| $9.19B+2.4% | $8.97B+0.4% | $8.94B+12.2% | $7.97B+4.5% | $7.63B+2.3% | ||
| $3.02B-1.2% | $3.06B-0.7% | $3.08B-0.7% | $3.1B-1.1% | $3.13B-1.5% | ||
| $6.49B0.0% | $6.49B0.0% | $6.49B0.0% | $6.49B+0.2% | $6.48B0.0% | ||
| $7.25B-1.7% | $7.38B-2.0% | $7.53B-1.8% | $7.66B-1.5% | $7.78B-19.7% | ||
| $29.48B+0.1% | $29.44B+0.8% | $29.21B+3.1% | $28.33B+1.1% | $28.03B-0.1% | ||
| $358.5M-17.0% | $432M+4.6% | $413.1M+1.2% | $408.4M+4.3% | $391.5M-7.7% | ||
| $3B-10.5% | $3.35B+1.8% | $3.29B+3.3% | $3.18B-39.9% | $5.3B-4.2% | ||
| $6.29B0.0% | $6.29B0.0% | $6.29B0.0% | $6.28B+38.1% | $4.55B0.0% | ||
| $305.1M-0.1% | $305.3M-97.2% | $11B+2.8% | $10.7B-3.2% | $11.05B-2.5% | ||
| $100K0.0% | $100K0.0% | $100K0.0% | $100K0.0% | $100K0.0% | ||
| $20.87B+1.6% | $20.55B-0.2% | $20.6B+2.3% | $20.14B+3.3% | $19.5B+1.2% | ||
| $18.65B+2.2% | $18.26B+0.3% | $18.21B+3.3% | $17.63B+3.9% | $16.98B+1.6% | ||
| $29.48B+0.1% | $29.44B+0.8% | $29.21B+3.1% | $28.33B+1.1% | $28.03B-0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Biogen's total assets?
- Biogen (BIIB) holds $29.5B in total assets, up 5.2% year over year.
- How much debt does Biogen have?
- Biogen carries $6.6B in total debt against $18.7B of shareholders' equity, a debt-to-equity ratio of 0.35.
- How much cash does Biogen have?
- Biogen holds $3.4B in cash and equivalents.
- Can Biogen cover its short-term obligations?
- Its current ratio is 3.06 — current assets exceed current liabilities.
- Where does Biogen's balance sheet data come from?
- Every line is extracted from Biogen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
